Benzinga | Mar 1, 2021 06:53AM EST

HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Lowers Price Target to $255

HC Wainwright & Co. analyst Edward White maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $257 to $255.